For example, TET2 and DNMT3A gene mutations are common in the early stages of PTCL pathogenesis, and HDAC1 and 2 mediate TET2 protein deacetylation and degradation via the ubiquitin–proteasome pathway [89]. This evidence concerns the gene HDAC1 and mature T-cell and NK-cell non-Hodgkin lymphoma.